GSK Initiates P-III Study of GSK3511294 (GSK’294) for the Treatment of Severe Asthma

March 18, 2021 Auto Bot Clinical Trials, GSK, Initiates, P-III study, severe asthma, Treatment 0

Shots:

  • The first patient has been dosed in the P-III SWIFT-2 trial assessing the safety and efficacy of GSK3511294 (GSK’294) in SEA
  • The planned P-III program involves three studies, SWIFT 1, SWIFT 2 and the NIMBLE study that will assess the efficacy and safety of GSK’294 in ~2,450 patients with severe eosinophilic asthma
  • GSK’294 (SC, every 6mos.) is an anti-IL-5 mAb, currently in development for the treatment of SEA and has progressed from P-I to P-III studies in three and a half years

Click here ­to­ read full press release/ article | Ref: GSK | Image: News Medical

The post GSK Initiates P-III Study of GSK3511294 (GSK’294) for the Treatment of Severe Asthma first appeared on PharmaShots.